Lotus Clinical Research, a Pasadena-based global specialty analgesic full-service contract research organization (CRO), has appointed Peggy Schrammel as Senior Vice President of CRO Services.
“Lotus Clinical Research is continuing with our rapid growth by focusing our efforts on increasing our infrastructure and human capital,” said Dr. Neil Singla, Lotus Clinical Research President and CEO. “Adding Peggy to our team adds depth to our leadership and positions us for exponential future growth in the analgesic CRO space.”
Singla also cited Schrammel’s experience, expertise, and ability to successfully deliver on the sale, design, and execution of programs in her previous roles with some of the industry’s largest CROs.
Prior to joining Lotus Clinical Research, Schrammel spent over 25 years in various senior leadership and management positions at several of the largest global CROs, most recently as Vice President, Scientific Affairs and Asia Pacific for Parexel in Boulder, Colorado, where she was responsible for growing the business and ensuring strong scientific support for both new opportunities and on-going projects.
At Lotus Clinical Research, Schrammel is responsible for leading business development efforts and assisting with further building our CRO infrastructure to further grow our business and fuel our anticipated growth.
“I am excited to be joining the established Lotus Clinical Research team,” Schrammel said. “Lotus Clinical Research is prepared for exponential growth in the analgesic drug development space. By delivering on their mission to reduce prescription drug misuse and abuse, Lotus’ team consistently thinks outside of the norm to develop strategies and pathways that help pharmaceutical companies bring their products to market.”
For more information about the Pasadena company, visit www.lotuscr.com.